15:45 - 16:45
Room: Hall 3

IP6: ARE EXISTING HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS INADEQUATE FOR ESTABLISHING VALUE FOR POTENTIALLY TRANSFORMATIVE GENE THERAPIES?

Moderator:

Kellie Meyer, PharmD, MPH, Senior Director, Global Health Economics, Xcenda, Palm Harbor, FL, USA

Panelists:

Ron Akehurst, PhD, Chairman, BresMed Health Solutions, Sheffield, UK

Clark Paramore, MSPH, Head of Value Demonstration, bluebird bio, Cambridge, MA, USA

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK